Earlier, the study concluded that patients who took the anti malarial drug hydroxychloroquine had a higher risk of death than those who did not, leading some researchers to discontinue clinical trials.
We are all involved in this collaboration and sincerely contribute to this extraordinary period of the new crown pandemic, the authors wrote in a June 4 statement We apologize for any embarrassment or inconvenience that may be caused. We apologize to you, the editor and the readers of the journal.
The study used data from more than 96000 new crown patients admitted to 671 hospitals on six continents by health analytics firm surgisphere Corporation, the report said. However, the company told peer reviewers that it would not disclose the complete data set used for the study because it would violate customer agreements and confidentiality requirements.
Surgisphere Corporation is one of the co authors of the study, sapan Desai. Reported that Desai did not sign the withdrawal application with the other three co authors.
The lancet wrote in a statement that it attaches great importance to the issue of scientific integrity and that there are many outstanding questions about the surgisphere and the data allegedly included in this study.
Earlier, trump had a two-week course of hydroxychloroquine after a driver of President trump tested positive for his new crown. But another study published earlier showed that the drug could not effectively prevent new crown.
Another study of 368 patients, published in the New England Journal of medicine in April, found that the two main outcomes of new crown patients treated with hydroxychloroquine were either death or critical, requiring ventilator use.
Read more about Musks Twitter bombardment of Bezos: spin off Amazon! Many institutions are deeply involved in LETV. Com. Sun Hongbin has earlier cut the flesh and ran the prospectus of Jingdong Hong Kong Stock: Tencent is the largest shareholder, Liu qiangdong, with 78.4% of the voting rights. Source: responsible editor of China news.com: Wang Fengzhi_ NT2541